Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

The PEP++ study protocol: a cluster-randomised controlled trial on the effectiveness of an enhanced regimen of post-exposure prophylaxis for close contacts of persons affected by leprosy to prevent disease transmission.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect Dis Subsets: MEDLINE
    • Publication Information:
      Original Publication: London : BioMed Central, [2001-
    • Subject Terms:
      Rifampin*/therapeutic use ; Leprosy*/drug therapy ; Leprosy*/prevention & control ; Leprosy*/diagnosis; Humans ; Post-Exposure Prophylaxis/methods ; Anti-Bacterial Agents/therapeutic use ; Clarithromycin/therapeutic use ; Randomized Controlled Trials as Topic
    • Abstract:
      Background: Leprosy is an infectious disease with a slow decline in global annual caseload in the past two decades. Active case finding and post-exposure prophylaxis (PEP) with a single dose of rifampicin (SDR) are recommended by the World Health Organization as measures for leprosy elimination. However, more potent PEP regimens are needed to increase the effect in groups highest at risk (i.e., household members and blood relatives, especially of multibacillary patients). The PEP++ trial will assess the effectiveness of an enhanced preventive regimen against leprosy in high-endemic districts in India, Brazil, Bangladesh, and Nepal compared with SDR-PEP.
      Methods: The PEP++ study is a cluster-randomised controlled trial in selected districts of India, Brazil, Bangladesh, and Nepal. Sub-districts will be allocated randomly to the intervention and control arms. Leprosy patients detected from 2015 - 22 living in the districts will be approached to list their close contacts for enrolment in the study. All consenting participants will be screened for signs and symptoms of leprosy and tuberculosis (TB). In the intervention arm, eligible contacts receive the enhanced PEP++ regimen with three doses of rifampicin (150 - 600 mg) and clarithromycin (150 - 500 mg) administered at four-weekly intervals, whereas those in the control arm receive SDR-PEP. Follow-up screening for leprosy will be done for each individual two years after the final dose is administered. Cox' proportion hazards analysis and Poisson regression will be used to compare the incidence rate ratios between the intervention and control areas as the primary study outcome.
      Discussion: Past studies have shown that the level of SDR-PEP effectiveness is not uniform across contexts or in relation to leprosy patients. To address this, a number of recent trials are seeking to strengthen PEP regimens either through the use of new medications or by increasing the dosage of the existing ones. However, few studies focus on the impact of multiple doses of chemoprophylaxis using a combination of antibiotics. The PEP++ trial will investigate effectiveness of both an enhanced regimen and use geospatial analysis for PEP administration in the study communities.
      Trial Registration: NL7022 on the Dutch Trial Register on April 12, 2018. Protocol version 9.0 updated on 18 August 2022 https://www.onderzoekmetmensen.nl/en/trial/23060.
      (© 2024. The Author(s).)
    • References:
      BMJ Open. 2016 Nov 17;6(11):e013633. (PMID: 27856484)
      PLoS Negl Trop Dis. 2021 Aug 23;15(8):e0009654. (PMID: 34424909)
      PLoS Negl Trop Dis. 2021 Jan 21;15(1):e0009031. (PMID: 33476343)
      Int J Infect Dis. 2019 Nov;88:65-72. (PMID: 31499206)
      N Engl J Med. 2023 May 18;388(20):1843-1852. (PMID: 37195940)
      PLoS Negl Trop Dis. 2019 Apr 5;13(4):e0007302. (PMID: 30951526)
      J Dtsch Dermatol Ges. 2017 Aug;15(8):801-827. (PMID: 28763601)
      BMC Infect Dis. 2019 Dec 5;19(1):1033. (PMID: 31805862)
      Am J Trop Med Hyg. 2005 Apr;72(4):443-8. (PMID: 15827283)
      Int J Lepr Other Mycobact Dis. 1999 Jun;67(2):119-28. (PMID: 10472363)
      Lepr Rev. 2004 Dec;75(4):376-88. (PMID: 15682975)
      J Infect. 2000 Sep;41(2):137-42. (PMID: 11023757)
      Lepr Rev. 2006 Dec;77(4):298-310. (PMID: 17343217)
      Infect Dis Poverty. 2016 Jun 08;5(1):46. (PMID: 27268059)
      BMJ. 2008 Apr 5;336(7647):761-4. (PMID: 18332051)
      Br Med Bull. 2006;77-78:103-21. (PMID: 17090777)
      PLoS Negl Trop Dis. 2022 Dec 16;16(12):e0010972. (PMID: 36525390)
      BMC Infect Dis. 2023 May 9;23(1):310. (PMID: 37161571)
      Lancet Glob Health. 2021 Jan;9(1):e81-e90. (PMID: 33129378)
      PLoS Negl Trop Dis. 2020 Sep 16;14(9):e0008583. (PMID: 32936818)
      BMC Infect Dis. 2018 Oct 05;18(1):506. (PMID: 30290790)
    • Contributed Indexing:
      Keywords: Blanket campaigns; Clarithromycin; High-endemic areas; Leprosy; Post-exposure prophylaxis; Rifampicin
    • Accession Number:
      VJT6J7R4TR (Rifampin)
      0 (Anti-Bacterial Agents)
      H1250JIK0A (Clarithromycin)
    • Publication Date:
      Date Created: 20240220 Date Completed: 20240222 Latest Revision: 20240224
    • Publication Date:
      20250114
    • Accession Number:
      PMC10877766
    • Accession Number:
      10.1186/s12879-024-09125-2
    • Accession Number:
      38378497